Awardee OrganizationUNIVERSITY OF PUERTO RICO MED SCIENCES
Description
Abstract Text
PROJECT SUMMARY
Cervical cancer (CC) is the fourth most common female malignancy worldwide. Mortality rates are three times
higher in Latin America and the Caribbean than in the United States, and Puerto Rico (PR) has the highest
age-adjusted incidence for cervical cancer in the US despite of vaccination. Persistent infection with high-risk
human papilloma virus (hr-HPV) types is a necessary, but not sufficient to cause cervical cancer. Other yet
unknown cofactors are required to promote hr-HPH persistence and progression to cancer, however these
pathways are not completely understood. Besides HPV infections, the key factors that promote cancer
progression likely reside in the cervical environment, notably its local microbiome. Preliminary evidence
suggests that increased bacterial diversity and reduction in Lactobacillus are associated with High grade
squamous intraepithelial lesion (HSIL), however, except for preliminary data from our group that studied
cervical yeast, we have not yet understood the importance of the fungal communities and other combined
metabolic and host factors on disease progression. Here we propose to comprehensively study virus-
microbiota-host interactions, using state of the art sequencing technologies and novel bioinformatic algorithms
to address a malignancy, that is characterized by health disparities in the US and globally. Our overarching
goal is to identify microbial inter-species interactions and host factors that control hr-HPV persistence
and cervical disease. We will leverage samples and data already collected from over 300 participants in a
cross-sectional pilot study cohort, and to additionally select 200 participants to follow up longitudinally.
In Aim 1, we will quantify the cervicovaginal bacterial and fungal community composition and metabolome
cross-sectionally, differentiating women with or without cervical dysplasia and presence or absence of high risk
(hr) HPV. In Aim 2 we will identify bacterial and fungal strains, functional gene pathways and metabolites that
over a longitudinal timeseries distinguish women without cervical disease (NILM - HPV negative and low-risk),
from high-risk HPV infected women who progress to high grade dysplasia. Having shotgun metagenomics data
from selected patients longitudinally is unique to be able to understand gene and functional changes of key
taxa to inform on their role in progression or regression. We hypothesize that there will be genomic bacterial
strains that differentiate women without lesions and with cervical disease and that multiple levels of omics data,
including the microbiome, the metabolome and the cytokine profiles may have higher predictive value than
HPV risk alone. This work will develop a strong platform for a long standing and central question regarding
cervical disease in Hispanics and will lay the foundation for elucidating the mechanisms by which
microbiomes affect HPV persistence and dysplasia.
Public Health Relevance Statement
PROJECT NARRATIVE
Human papilloma virus (HPV) has been established as a causative agent of cervical cancer (CC),
and Hispanic woman in Puerto Rico have the highest age-adjusted incidence compared to women
in the US. Persistent infection with high-risk human papilloma virus (hr-HPV) types is a necessary,
but not sufficient to cause cervical cancer. We hypothesize that the key factors that promote cancer
progression likely reside in the cervical environment, notably its local multi-kingdom microbiome.
Here we propose to comprehensively study crossectionally and longitudinally, the relationship
between HPV, lower genital tract commensal bacteria and fungi, the metabolome and the immune
response and cervical cancer.
National Institute on Minority Health and Health Disparities
CFDA Code
DUNS Number
948108063
UEI
KWTAB1GYM4L9
Project Start Date
01-September-1997
Project End Date
31-May-2027
Budget Start Date
01-June-2024
Budget End Date
31-May-2025
Project Funding Information for 2024
Total Funding
$292,098
Direct Costs
$279,572
Indirect Costs
$96,012
Year
Funding IC
FY Total Cost by IC
2024
National Institute on Minority Health and Health Disparities
$292,098
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 5U54MD007600-38 9342
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5U54MD007600-38 9342
Patents
No Patents information available for 5U54MD007600-38 9342
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5U54MD007600-38 9342
Clinical Studies
No Clinical Studies information available for 5U54MD007600-38 9342
News and More
Related News Releases
No news release information available for 5U54MD007600-38 9342
History
No Historical information available for 5U54MD007600-38 9342
Similar Projects
No Similar Projects information available for 5U54MD007600-38 9342